Moderna

MRNA-Q

Analysis and Opinions about MRNA-Q

Signal
Opinion
Expert
COMMENT
COMMENT
July 21, 2020

They were one of the first to enter the COVID vaccine race. They stock has shot up from $16 to $90. They don't make any money, though. They're making progress with their vaccine, and are still testing it to ensure safe, mass use. He doesn't think they'll make much money if they produce the vaccine (JNJ said they wouldn't charge much for their vaccine). But Moderna would prove the quality of its technology if the produce an effetive vaccine. There's been heavy insider selling at oderna, but that's likely triggered by the huge stock run-up.

Show full opinionHide full opinion
Moderna (MRNA-Q)
July 21, 2020

They were one of the first to enter the COVID vaccine race. They stock has shot up from $16 to $90. They don't make any money, though. They're making progress with their vaccine, and are still testing it to ensure safe, mass use. He doesn't think they'll make much money if they produce the vaccine (JNJ said they wouldn't charge much for their vaccine). But Moderna would prove the quality of its technology if the produce an effetive vaccine. There's been heavy insider selling at oderna, but that's likely triggered by the huge stock run-up.

COMMENT
COMMENT
May 18, 2020

As mentioned in our May report to Stockchase subscribers, Moderna (with NIH) began Phase 1 testing for a vaccine back in March. If the drug pasts future tests, Moderna and Swiss drugmaker, Lonza, will produce the drug together. Monday’s news puts Moderna as the frontrunner in the vaccine race and lifted its stock 27% to 84% year-to-date.

Show full opinionHide full opinion
Moderna (MRNA-Q)
May 18, 2020

As mentioned in our May report to Stockchase subscribers, Moderna (with NIH) began Phase 1 testing for a vaccine back in March. If the drug pasts future tests, Moderna and Swiss drugmaker, Lonza, will produce the drug together. Monday’s news puts Moderna as the frontrunner in the vaccine race and lifted its stock 27% to 84% year-to-date.

Showing 1 to 2 of 2 entries
  • «
  • 1
  • »

Moderna(MRNA-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Moderna is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Moderna(MRNA-Q) Frequently Asked Questions

What is Moderna stock symbol?

Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q

Is Moderna a buy or a sell?

In the last year, there was no coverage of Moderna published on Stockchase.

Is Moderna a good investment or a top pick?

Moderna was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Moderna.

Why is Moderna stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Moderna worth watching?

0 stock analysts on Stockchase covered Moderna In the last year. It is a trending stock that is worth watching.

What is Moderna stock price?

On 2020-09-23, Moderna (MRNA-Q) stock closed at a price of $67.16.